Charles Alvin Meloy

Director Charles Alvin Meloy sold 83,334 shares at $187.12 blended average for $15.6M on 2026-06-16 via 10b5-1 plan; retains 851.5K shares.

Charles Alvin Meloy executed 3 separate sales totaling 83,334 shares for $15,593,331.53 on 2026-06-16 at prices ranging from $186.36 to $187.68, reducing his holdings by 8.9% to 851,530 shares. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled and not discretionary. His cross-ticker track record shows 20 prior sells with an average 90-day return of +10.4%, but those historical outcomes do not characterize the mechanical nature of this scheduled transaction. The current stock price of $185.48 is 13.5% below the 52-week high of $214.51, and the stock has declined 9.8% over the trailing 30 days and 2.5% over 90 days. Given the scheduled nature of the 10b5-1 plan and his continued substantial holdings post-sale, this filing reflects portfolio execution against a predetermined schedule rather than a discretionary positioning decision.

Director Meloy sells ~15,700 shares worth nearly $3M in single-day execution while stock trades below its 52-week high.

Director Meloy Charles Alvin executed a substantial portfolio reduction, selling roughly 15,700 shares across seven transactions over two trading days totaling nearly $3M. This represents his 30th through 36th open-market sale in the past three years—a pattern of consistent selling with no offsetting purchases. His prior sales at this company show conflicting timing signals: four of his five previous exits were well-timed over the longer term, but one was poorly-timed near-term, suggesting mixed execution precision. The company remains profitable with strong revenue growth, yet Meloy is selling as the stock trades noticeably below its 52-week high, which typically might suggest weakness, though the stock has gained modestly over the past quarter despite the broader selling pressure. His track record shows he has sold repeatedly but without the kind of near-term accuracy that would clearly signal this trade as prescient—this is a director reducing exposure, not a strategically timed bet.

Director Meloy sells 15,714 shares at $193.32–$198.49 for $3.1M (7 transactions, 2026-04-06/07)

Meloy Charles Alvin, a Director at Diamondback Energy, executed 7 separate sales totaling 15,714 shares (15.7K shares) for $3,071,668.21 ($3.1M) at prices ranging from $193.32 to $198.49 on April 6–7, 2026, reducing holdings by 1.6% to 950,578 shares. The blended average sale price of $195.47 sits near the 52-week high of $202.19 and well above the current price of $186.47, suggesting the sales occurred during a favorable price window. At the broader portfolio level, Meloy retains significant holdings (950.6K shares), indicating continued material exposure to the company despite the reduction. The timing of these sales relative to future stock performance cannot be assessed without forward-looking data beyond the filing date.

Director Meloy Charles Alvin sold 15,714 shares at $181.50 avg for $2.9M (2026-03-09/10)

Meloy Charles Alvin executed 13 separate sales totaling 15,714 shares for $2,852,036.55 across March 9–10, 2026, reducing his FANG holdings from 982.0K to 966.3K shares (-1.6%). The sales occurred across a $180.45–$186.16 price range on March 9 and $177.09–$182.03 on March 10, with a blended average of $181.50—near the 52-week high of $182.86 and well above the current price of $176.64. At the same-ticker level, Alvin's five prior FANG sales (December 2025 through early February 2026) showed consistent positive 30-day returns (+9.9% to +11.6%), though 90-day outcomes are largely unmeasured at this ticker. His cross-ticker track record of five open-market sells shows a 0.00% well-timed rate at the 90-day horizon, meaning prior sales were followed by stock appreciation rather than decline. FANG's fundamentals remain robust—$3.9B quarterly revenue, $1.0B net income, +35.8% annual revenue growth, and a P/E of 19.76—offering no obvious operational distress signal. The systematic execution of multiple tranches near recent highs, combined with historically positive post-sale returns and absence of material company deterioration, suggests this is a liquidity or predetermined event rather than a response to negative information asymmetry.

Director Meloy sells 62,805 shares at avg $161.09 for $10.1M; retains 982.0K shares post-sale.

Director Meloy Charles Alvin executed 4 separate sales totaling 62,805 shares for $10,117,126.13 on February 2–3, 2026, at an average price of $161.09 per share, reducing his stake by 6.0%. The stock currently trades at $168.99, above the blended sale price and near its 52-week high, reflecting substantial recent momentum (30-day: +15.0%, 90-day: +20.0%). Meloy's cross-ticker track record shows 1 prior sell with a 30d return of +9.9%, and his only measurable same-ticker sale (December 4, 2025) also posted a +9.9% 30d return—both instances where the stock moved higher after his sales. FANG's fundamentals remain strong: net income of $1,018,000,000.00, revenue growth of +31.6% year-over-year, and a modest P/E of 11.54. The current sale occurs during a period of sustained upward price movement and favorable earnings backdrop, and he retains substantial holdings (982.0K shares), so the disposal does not signal an exit of conviction.

Director Meloy Charles Alvin sold 377,911 shares of FANG at $138.61 for $52.4M, reducing holdings by -26.6%

Director Meloy Charles Alvin executed a substantial sale of 377,911 shares (377.9K shares) at $138.61 on 2025-12-04, generating $52,382,243.71 in proceeds and reducing his holdings from 1,422,775 shares to 1,044,864 shares. The transaction represents a -26.6% reduction in his pre-transaction holdings at a price $19.91 below the current market price of $157.52. Against the company's strong fundamentals—$3.9B in quarterly revenue, $1.0B net income, +31.6% annual revenue growth, and a relatively low P/E of 10.76—the directional signal of a significant divestiture by a board member in a capital-efficient energy company warrants investor scrutiny into the timing and rationale for this share reduction.